Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice.

Brian T, Jameson MB.

J Prim Health Care. 2018 Oct;10(3):210-214. doi: 10.1071/HC17055.

PMID:
31039935
2.

Sentinel node biopsy for melanoma: New Zealand indication guidelines in practice.

Brian T, McEwan W, Jameson MB.

J Plast Reconstr Aesthet Surg. 2019 Jan;72(1):137-171. doi: 10.1016/j.bjps.2018.10.001. Epub 2018 Nov 2. No abstract available.

PMID:
30424975
3.

The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells.

Lobb RJ, Jacobson GM, Cursons RT, Jameson MB.

Int J Mol Sci. 2018 Oct 15;19(10). pii: E3167. doi: 10.3390/ijms19103167.

4.

Comparative Safety and Pharmacokinetic Evaluation of Three Oral Selenium Compounds in Cancer Patients.

Evans SO, Jacobson GM, Goodman HJB, Bird S, Jameson MB.

Biol Trace Elem Res. 2019 Jun;189(2):395-404. doi: 10.1007/s12011-018-1501-0. Epub 2018 Sep 5.

PMID:
30187284
5.

Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease.

Rider NL, Jameson MB, Creech CB.

J Pediatric Infect Dis Soc. 2018 May 9;7(suppl_1):S2-S5. doi: 10.1093/jpids/piy008. Review.

6.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
7.

Optimising Selenium for Modulation of Cancer Treatments.

Evans SO, Khairuddin PF, Jameson MB.

Anticancer Res. 2017 Dec;37(12):6497-6509. Review.

PMID:
29187424
8.

The Role of Oxaliplatin in Chemoradiotherapy for Rectal Cancer.

Wewala NT, Jameson MB.

Asia Pac J Clin Oncol. 2017 Dec;13(6):341-342. doi: 10.1111/ajco.12744. No abstract available.

PMID:
29134793
9.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.

PMID:
28729151
10.

Development of a qPCR Method to Measure Mitochondrial and Genomic DNA Damage with Application to Chemotherapy-Induced DNA Damage and Cryopreserved Cells.

Evans SO, Jameson MB, Cursons RT, Peters LM, Bird S, Jacobson GM.

Biology (Basel). 2016 Oct 8;5(4). pii: E39.

11.

Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.

Han CH, Kilfoyle DH, Hill AG, Jameson MB, McKeage MJ.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1479-1490. Epub 2016 Aug 23. Review.

PMID:
27539508
12.

Impact of geriatric assessment on the management of older adults with head and neck cancer: A pilot study.

Neve M, Jameson MB, Govender S, Hartopeanu C.

J Geriatr Oncol. 2016 Nov;7(6):457-462. doi: 10.1016/j.jgo.2016.05.006. Epub 2016 Jun 13.

PMID:
27313080
13.

Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck.

Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB.

World J Clin Oncol. 2015 Oct 10;6(5):166-73. doi: 10.5306/wjco.v6.i5.166.

14.

Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer.

Mix M, Ramnath N, Gomez J, de Groot C, Rajan S, Dibaj S, Tan W, Rustum Y, Jameson MB, Singh AK.

World J Clin Oncol. 2015 Oct 10;6(5):156-65. doi: 10.5306/wjco.v6.i5.156.

15.

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.

Clin Genitourin Cancer. 2015 Feb;13(1):50-8. doi: 10.1016/j.clgc.2014.07.002. Epub 2014 Jul 15.

PMID:
25163397
16.

Adding selenium to chemotherapy and radiation in haematological malignancies: clinical trials are justified.

Jameson MB, Evans SO.

Acta Haematol. 2014;132(2):254-5. No abstract available.

PMID:
24903090
17.

Review of high-dose intravenous vitamin C as an anticancer agent.

Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP.

Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37. doi: 10.1111/ajco.12173. Review.

PMID:
24571058
18.

Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen.

Gunawardena I, Arendse M, Jameson MB, Plank LD, Gregor RT.

ANZ J Surg. 2015 Nov;85(11):843-8. doi: 10.1111/ans.12424. Epub 2013 Oct 31.

PMID:
24171785
19.

A randomized pilot trial of dietary modification for the chemoprevention of noninvasive bladder cancer: the dietary intervention in bladder cancer study.

Parsons JK, Pierce JP, Natarajan L, Newman VA, Barbier L, Mohler J, Rock CL, Heath DD, Guru K, Jameson MB, Li H, Mirheydar H, Holmes MA, Marshall J.

Cancer Prev Res (Phila). 2013 Sep;6(9):971-8. doi: 10.1158/1940-6207.CAPR-13-0050. Epub 2013 Jul 18. Erratum in: Cancer Prev Res (Phila). 2013 Dec;6(12):1378.

20.

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.

Harvey VJ, Sharples KJ, Isaacs RJ, Jameson MB, Jeffery GM, McLaren BR, Pollard S, Riley GA, Simpson AB, Hinder VA, Scott JN, Dzhelali MV, Findlay MP.

Ann Oncol. 2013 Jul;24(7):1828-34. doi: 10.1093/annonc/mdt065. Epub 2013 Mar 4.

PMID:
23463624
21.

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS.

BMC Cancer. 2012 Oct 25;12:496. doi: 10.1186/1471-2407-12-496.

22.

Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma.

Sanders JG, Smith KG, Jameson MB, de Groot C, White J.

J Laryngol Otol. 2012 Nov;126(11):1121-6. doi: 10.1017/S0022215112002009. Epub 2012 Sep 19.

PMID:
22989730
23.

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators.

J Thorac Dis. 2010 Dec;2(4):199-204. doi: 10.3978/j.issn.2072-1439.2010.02.04.1.

24.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB.

BMC Cancer. 2011 Oct 7;11:432. doi: 10.1186/1471-2407-11-432.

25.

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).

Jameson MB, Head M.

Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1315-26. doi: 10.1517/17425255.2011.614389. Epub 2011 Aug 26. Review.

PMID:
21870897
26.

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF.

Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. doi: 10.1158/1078-0432.CCR-10-2490. Epub 2011 Mar 29.

27.

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.

Head M, Jameson MB.

Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214.

PMID:
20050824
28.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.

Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.

PMID:
20012293
29.

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J.

Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5.

PMID:
19409645
30.

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC.

Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2553-9. doi: 10.1167/iovs.08-2068. Epub 2009 Apr 22.

PMID:
19387077
31.

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E.

Br J Cancer. 2008 Dec 16;99(12):2006-12. doi: 10.1038/sj.bjc.6604808.

32.

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.

Li J, Jameson MB, Baguley BC, Pili R, Baker SD.

Clin Cancer Res. 2008 Apr 1;14(7):2102-10. doi: 10.1158/1078-0432.CCR-07-1475.

33.

Early experience with novel immunomodulators for cancer treatment.

Thotathil Z, Jameson MB.

Expert Opin Investig Drugs. 2007 Sep;16(9):1391-403. Review.

PMID:
17714025
34.

Chemotherapy prescription patterns in colon cancer: a patterns-of-care survey in New Zealand.

Thotathil ZS, Long JE, Kennedy I, Jameson MB, Adams J, Kuper M.

N Z Med J. 2007 Jul 20;120(1258):U2636.

PMID:
17653254
35.

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.

Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI, Waller S; Cancer Research (UK) Phase I/II Trials Committee.

Cancer Chemother Pharmacol. 2007 Apr;59(5):681-7. Epub 2006 Sep 23.

PMID:
17021822
36.

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB.

Clin Cancer Res. 2006 Mar 15;12(6):1776-84.

37.

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P; Phase I/II Trials Committee of Cancer Research UK.

Br J Cancer. 2003 Jun 16;88(12):1844-50.

38.

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.

Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC.

Br J Cancer. 2002 Jun 17;86(12):1937-42.

39.

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC.

Clin Chim Acta. 2001 Dec;314(1-2):159-66.

PMID:
11718691
40.

Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.

Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC.

Xenobiotica. 2001 May;31(5):277-93.

PMID:
11491389
41.

Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies.

Jameson MB, Roberts E, Nixon J, Probert JC, Braatvedt GD.

Clin Oncol (R Coll Radiol). 1997;9(2):119-21.

PMID:
9135897
42.

Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres.

Jameson MB, Evans BD, Gray DH, Forgeson GV, Allan SG, Humm G, Thomson J, Thompson PI, Harvey VJ.

Aust N Z J Med. 1995 Jun;25(3):224-9.

PMID:
7487690

Supplemental Content

Loading ...
Support Center